Inflammatory Bowel Diseases: World Drug Market 2011-2021
NEW YORK, Aug. 22, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Inflammatory Bowel Diseases: World Drug Market 2011-2021
http://www.reportlinker.com/p0595028/Inflammatory-Bowel-Diseases-World-Drug-Market-2011-2021.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
How will the market for inflammatory bowel disease (IBD) treatments perform from 2011? Our new report shows you potential pharmaceutical revenues to 2021, discussing opportunities and market prospects.
Discover potential IBD drug revenues at total world, submarket, product and national levels. Through our research and analysis we aim to save you time and help in your decisions.
See how drugs such as Remicade, Humira, Cimzia, Asacol, Pentasa and Entocort can perform to 2021, finding potential revenues. How will competition affect the bowel disorder drug market?
Our study covers Warner Chilcott, Shire, Prometheus, Kyorin, Merck, UCB, Schering-Plough, J&J and other companies. Discover commercial prospects for biological and non-biological drugs for IBD. Receive data you need.
There is a strong R&D pipeline for treating Crohn's disease and ulcerative colitis. We cover monoclonal antibodies, small molecules, antibiotics and other agents. Find R&D trends.
Our new report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now.
Analysis with revenues, future growth rates, market shares, opinions and discussions
In our report you find revenue forecasts, growth rates, market shares, a SWOT/STEP review, an R&D review and opinions from our survey. You receive 78 tables and charts and three research interviews (shown in the accompanying lists).
Inflammatory Bowel Diseases: World Drug Market 2011-2021 shows you opportunities, challenges and revenue forecasts
Our report gives you the following advantages:
• Find revenue predictions to 2021 for the world IBD drug market and its submarkets, seeing revenue growth
• Discover revenue forecasts to 2021 for leading products, assessing market potentials
• See revenue forecasts to 2021 for leading national markets - US, Japan, Germany, France, UK, Spain, Italy, China and India
• Assess companies providing IBD treatments, discovering their activities and outlooks
• Find out how the IBD drug industry can change and adapt from 2011 to 2021
• Investigate competition and opportunities influencing the industry and market
• See what will stimulate and restrain the industry and market from 2011
• Review the R&D pipeline for IBD, assessing its potential
• Investigate commercial requirements, identifying therapeutic needs and opportunities
• Analyse opportunities and challenges for established and emerging companies
• View opinions from our survey, receiving three full interview transcripts.
There, you find a distinctive mix of quantitative and qualitative analysis with independent predictions. We tackle crucial questions on inflammatory bowel diseases, helping you to stay ahead.
Order our report now to gain industry and market analysis for bowel disorders
Our report is for everybody interested in industry and market analysis for treating inflammatory bowel diseases. Find trends and answers. Don't miss out - please order our report now.
Table of Contents
1. Executive Summary
1.1 Inflammatory Bowel Disease Market Overview
1.2 Aims, Scope and Format of the Report
1.3 Chapter Outlines
1.4 Research and Analysis Methods
2. Introduction to the Inflammatory Bowel Disease Market
2.1 Definition of Inflammatory Bowel Disease (IBD)
2.2 Types of IBD
2.3 Signs, Symptoms and Associated Conditions
2.3.1 Bleeding Ulcers, Fistulae, Bowel Perforations, Toxic Megacolon
2.3.2 Pyoderma Gangrenosum
2.3.3 Primary Sclerosing Cholagitis
2.3.4 Malnutrition, Poor Nutrient Absorption and Stunting
2.4 Ulcerative Colitis
2.5 Crohn's Disease
2.6 Indeterminate Colitis: Distinguishing Crohn's Disease from Ulcerative Colitis
2.7 What Causes Inflammatory Bowel Disease?
2.7.1 Genetic Factors
2.7.2 Environmental Factors
2.8 How Common is Inflammatory Bowel Disease?
2.8.1 Geographical Variations in Rates of IBD
2.9 Socioeconomic Costs of IBD
2.9.1 The Individual Cost of IBD
3. Treatments for Inflammatory Bowel Diseases
3.1 Treatment Goals
3.2 Drug Classes Used in IBD Treatment
3.2.1 Aminosalicylates
3.2.2 Corticosteroids
3.2.3 Immunomodulators
3.2.4 Monoclonal Antibodies
3.3 Surgery
3.3.1 Surgery for Ulcerative Colitis
3.3.2 Surgery for Crohn's Disease
3.4 Alternative Treatments
3.4.1 Faecal Bateriotherapy and Pre/Probiotics
3.4.2 Helminthic Therapy
3.4.3 Complementary Medicine
3.5 Treatment Protocol
3.5.1 Recent Trial Data
4. The World Inflammatory Bowel Disease Market, 2011-2021
4.1 Non-Biological Drugs
4.1.1 IBD-Specific Drugs (Intestinal Anti-Inflammatories)
4.1.2 Drugs Not Specific to IBD
4.2 Biological Drugs
4.3 Total IBD Market
4.4 Market Shares by Disease Type
4.5 Market Forecast: World Inflammatory Bowel Disease Sales, 2011-2021
4.6 Market Forecast: World Sales by Disease Type, 2011-2021
4.7 Market Forecast: World Sales by Therapy Type, 2011-2021
5. Market Prospects for Leading IBD Drugs, 2011-2021
5.1 Intestinal Anti-Inflammatory Drugs (IAIs/Non Biological Drugs)
5.2 Asacol (Mesalazine) - Warner Chilcott
5.2.1 Asacol: Information
5.2.2 Asacol Forecast and Analysis, 2011-2021
5.3 Pentasa (mesalazine) - Shire/Ferring
5.3.1 Pentasa: Information
5.3.2 Pentasa: Forecast and Analysis, 2011-2021
5.4 Entocort (budenoside) - AstraZeneca, Prometheus
5.4.1 Entocort: Information
5.4.2 Entocort: Forecast and Analysis, 2011-2021
5.5 Lialda (mesalazine) - Shire
5.5.1 Lialda: Information
5.5.2 Lialda: Forecast and Analysis, 2011-2021
5.6 Salofalk (mesalazine) - Dr. Falk
5.6.1 Salofalk: Information
5.6.2 Salofalk: Forecast and Analysis, 2011-2021
5.7 Other IAIs
5.8 Biological Drugs Used to Treat IBD
5.9 Remicade (infliximab) - Merck & Co., Schering-Plough, Johnson & Johnson
5.9.1 Remicade: Information
5.9.2 Remicade: Forecast and Analysis, 2011-2021
5.10 Humira (adalimumab) - Abbott
5.10.1 Humira: information
5.10.2 Humira: Forecast and Analysis, 2011-2021
5.11 Cimzia (certolizumab pegol) - UCB
5.11.1 Cimzia: Information
5.11.2 Cimzia: Forecast and Analysis, 2011-2021
5.12 Tysabri (natalizumab) - Biogen Idec/Elan
5.12.1 Tysabri: Information
5.12.2 Tysabri: Forecast and Analysis, 2011-2021
6. The R&D Pipeline for Inflammatory Bowel Disease, 2011-2021
6.1 Monoclonal Antibodies
6.1.1 HuZAF (fontolizumab) - Biogen Idec
6.1.2 Stelara (uskinamab) - Johnson & Johnson
6.1.3 Vedolizumab (MLN02) - Takeda
6.1.4 Simponi (golimumab) - Johnson & Johnson
6.2 Small Molecules
6.2.1 Tetomilast - Otsuka
6.2.2 Firategrast -GlaxoSmithKline
6.3 Antibiotics
6.3.1 Rifaximin - Salix Pharmaceuticals
6.3.2 Myconda - Giaconda
6.4 Nicotine and Buproprion
6.5 Alicaforsen - Isis
6.6 Alequel - Enzo
6.7 MAP Vaccine
6.8 Autologous Stem Cell Transplantation for Crohn's Disease
6.9 Technologies That Deliver Drugs to Affected Parts of the GI Tract
7. Drivers and Restraints in the Inflammatory Bowel Disease Drug Market, 2011-2021
7.1 SWOT Analysis of the IBD Market
7.2 Market Drivers
7.2.1 Increasing Disease Incidence
7.2.2 Better Diagnosis
7.2.3 Nature of the Disease
7.2.4 Delivery Systems
7.2.5 Biological Drugs
7.3 Market Restraints
7.3.1 Lack of Understanding of Disease Aetiology
7.3.2 Compliance
7.3.3 Limits of Biologics
7.3.4 A Cure or Vaccine
8. Leading National Markets for Inflammatory Bowel Disease Treatments, 2011-2021
8.1 Leading National Markets for IBD, 2011-2021
8.2 The US IBD Market: Forecast and Outlook, 2011-2021
8.3 The Japanese IBD Market: Forecast and Outlook, 2011-2021
8.4 Leading European IBD Markets: Forecasts and Outlook, 2011-2021
8.4.1 The German IBD Market, 2011-2021
8.4.2 The French IBD Market, 2011-2021
8.4.3 The Italian IBD Market, 2011-2021
8.4.4 The Spanish IBD Market, 2011-2021
8.4.5 The UK IBD Market, 2011-2021
8.5 Top 5 EU Markets for IBD Drugs, 2011-2021
8.6 IBD Drugs in Emerging Markets
8.6.1 Chinese IBD Market: Forecast and Outlook, 2011-2021
8.6.2 Indian IBD Market: Forecast and Outlook, 2011-2021
8.7 IBD Revenues from the Two Leading Emerging Markets, 2011-2021
8.8 Revenues for IBD Drugs in the Rest of the World: Forecast and Outlook, 2011-2021
8.9 Global IBD Market by Region, 2010
9. Leading Companies in the Industry and Market
9.1 The Largest Companies by Revenue in the Intestinal Anti-Inflammatory Market
9.2 Warner Chilcott
9.3 Shire Pharmaceuticals Group
9.4 Prometheus Laboratories
9.5 Ferring Pharmaceuticals
9.6 Kyorin Pharmaceutical Co.
10. Research Interviews from Our Survey
10.1 Professor John Hermon-Taylor, King's College London
10.1.1 The Significance of MAP in Crohn's
10.1.2 Rising Incidence of IBD
10.1.3 Defining IBD
10.1.4 Timeframe of MAP Vaccine
10.1.5 Antibiotic Activity of Other Crohn's Treatments
10.1.6 Alternative Treatments
10.1.7 Ethics of Crohn's Drug Development
10.1.8 The Impact of a Vaccine on the Market
10.1.9 On Claims that MAP is Not Implicated in CD
10.2 Marco Greco, Chairman, European Federation of Crohn's and Ulcerative Colitis Associations
10.2.1 Public Awareness of IBD
10.2.2 The Differences between European Countries
10.2.3 Drug Companies and Their Involvement in Awareness Campaigns
10.2.4 Unmet Medical Needs
10.3 Professor Thomas Barody, Director, Centre for Digestive Diseases, Sydney
10.3.1 Mycobacterium Avium Paratuberculosis (MAP) Infection and IBD Aetiology
10.3.2 IBD and HIV/AIDS
10.3.3 Monoclonal Antibodies and Immunosuppressant Treatments
10.3.4 Potential Cure?
10.3.5 Remicade and MAP
10.3.6 Genotyping
10.3.7 Crohn's vs. Colitis
10.3.8 Future Therapies
10.3.9 The Potential and Future of Myoconda
11. Conclusions
11.1 IBD Market to Grow from 2011 to 2021
11.2 Non-Biologic Treatments
11.3 Biologic Treatments
11.4 Improvements Needed in IBD Treatments
11.5 Future IBD Treatments: R&D Efforts Promising
11.6 The IBD Sector: Looking to the Future Confidently
List of Tables
Table 2.1 World Incidence Rates for IBD, 2011
Table 2.2 Geographical Variations in the Incidence of IBD, 2010
Table 2.3 Misdiagnosis of IBD in Developing Countries, 2011
Table 3.1 Drug Types Used to treat IBD, 2011
Table 3.2 Drugs Used to Treat IBD, 2011
Table 4.1 Total IBD Market Forecast with Main Submarkets ($m), 2010-2021
Table 4.2 Global IBD Market Forecast ($m), 2010-2021
Table 4.3 World IBD Market Forecasts by Disease ($m), 2010-2021
Table 4.4 World IBD Market Shares (%) and Revenues ($m) by Disease Type, 2010, 2015 and 2021
Table 4.5 IBD Drug Market Forecasts ($m) by Therapy Type, 2010-2021
Table 5.1 Top 5 IAI Drugs ($m), 2010
Table 5.2 World Asacol Revenue Forecast ($m), 2010-2021
Table 5.3 World Pentasa Revenue Forecast ($m), 2010-2021
Table 5.4 World Entocort Revenue Forecast ($m), 2010-2021
Table 5.5 World Lialda Revenue Forecast ($m), 2010-2021
Table 5.6 World Salofalk Revenue Forecast ($m), 2010-2021
Table 5.7 Market Forecast for top IAI Drugs ($m), 2010-2021
Table 5.8 World Remicade Revenue Forecast ($m), 2010-2021
Table 5.9 World Humira Revenue Forecast ($m), 2010-2021
Table 5.10 World Cimzia Revenue Forecast ($m), 2010-2021
Table 5.11 World Tysabri Revenue Forecast ($m), 2010-2021
Table 5.12 Market Forecasts ($m) for Top Biological IBD Drugs, 2010-2021
Table 5.13 World IBD Drug Market Forecasts ($m) by Drug Class, 2010-2021
Table 6.1 R&D Pipeline for Anti-IBD Products, 2011
Table 7.1 SWOT Analysis of the World Inflammatory Bowel Disease Drug Market, 2011-2021
Table 8.1 Leading National Markets for IBD Treatments: Revenues ($m) and Market Shares (%), 2010, 2015 and 2021
Table 8.2 US IBD Drug Market Forecast ($m), 2010-2021
Table 8.3 Japanese IBD Drug Market Forecast ($m), 2010-2021
Table 8.4 German IBD Drug Market Forecast ($m), 2010-2021
Table 8.5 French IBD Drug Market Forecast ($m), 2010-2021
Table 8.6 Italian IBD Drug Market Forecast ($m), 2010-2021
Table 8.7 Spanish IBD Drug Market Forecast ($m), 2010-2021
Table 8.8 UK IBD Drug Market Forecast, ($m), 2010-2021
Table 8.9 IBD Drug Market in Top 5 EU Countries ($m), 2010-2021
Table 8.10 Chinese IBD Drug Market Forecast ($m), 2010-2021
Table 8.11 Indian IBD Drug Market Forecast ($m), 2010-2021
Table 8.12 IBD Drug Markets ($m) in the Two Leading Emerging Countries, 2010-2021
Table 8.13 IBD Drug Market in the Rest of the World ($m), 2010-2021
Table 8.14 Global IBD Market by Region: Revenues ($m) and Market Shares (%), 2010
Table 8.15 Leading National Market Forecasts for IBD Drugs ($m), 2010-2021
Table 9.1 Top Three Companies for IAIs: Revenues ($m) and Market Shares (%), 2010
Table 9.2 Warner Chilcott IBD Revenues ($m), 2010
Table 9.3 Shire Pharmaceuticals IBD Revenues ($m), 2010
Table 9.4 Prometheus Laboratories IBD Revenues ($m), 2010
Table 9.5 Diagnostic Tests for IBD Offered by Prometheus, 2011
List of Figures
Figure 2.1 Geographical Variations in the Incidence of IBD, 2010
Figure 3.1 Treatment Protocol for IBD, 2011
Figure 4.1 World IBD Drug Market Forecast ($m), 2010-2021
Figure 4.2 Crohn's Disease Market Forecast ($m), 2010-2021
Figure 4.3 Ulcerative Colitis Market Forecast ($m), 2010-2021
Figure 4.4 CD and UC Market Forecasts ($m), 2010-2021
Figure 4.5 UC and CD Market Shares (%), 2010
Figure 4.6 UC and CD Market Shares (%), 2015
Figure 4.7 UC and CD Market Shares (%), 2021
Figure 4.8 IBD Market Forecasts ($m) by Therapy Type, 2010-2021
Figure 4.9 IBD Drug Market Shares (%) By Therapy Type, 2010-2021
Figure 5.1 World Asacol Revenue Forecast ($m), 2010-2021
Figure 5.2 World Pentasa Revenue Forecast ($m), 2010-2021
Figure 5.3 World Entocort Revenue Forecast ($m), 2010-2021
Figure 5.4 World Lialda Revenue Forecast ($m), 2010-2021
Figure 5.5 World Salofalk Revenue Forecast ($m), 2010-2021
Figure 5.6 Market Forecast for Top IAI Drugs ($m), 2010-2021
Figure 5.7 World Remicade Revenue Forecast ($m), 2010-2021
Figure 5.8 World Humira Revenue Forecast ($m), 2010-2021
Figure 5.9 World Cimzia Revenue Forecast ($m), 2010-2021
Figure 5.10 World Tysabri Revenue Forecast ($m), 2010-2021
Figure 5.11 Market Forecasts for Top Biological IBD Drugs ($m), 2010-2021
Figure 8.1 National Market Shares (%), 2010
Figure 8.2 National Market Shares (%), 2015
Figure 8.3 National Market Shares (%), 2021
Figure 8.4 US IBD Drug Market Forecast ($m), 2010-2021
Figure 8.5 Japanese IBD Drug Market Forecast ($m), 2010-2021
Figure 8.6 US and Japanese IBD Drug Market Forecasts ($m), 2010-2021
Figure 8.7 IBD Drug Sales ($m) in Top 5 EU Countries, 2010-2021
Figure 8.8 IBD Drug Markets ($m) in the Two Leading Emerging Countries, 2010-2021
Figure 8.9 IBD Drug Market in the Rest of the World ($m), 2010-2021
Figure 8.10 Global IVD Market Shares (%) by Region, 2010
Figure 9.1 Top 3 Companies for IAIs: Market Shares (%), 2010
Companies Listed
Abbott Laboratories
Amalyte Pharmaceuticals
ARCA
AstraZeneca
Atlantic Pharmaceuticals
Biogen Idec
Cambridge Antibody Technology
Celltech Pharmaceuticals
Centocor Ortho Biotech
ChemoCentryx
Centre for Digestive Diseases, Sydney
China Medical
Cosmo Pharmaceuticals
Crohn's and Colitis Foundation of America
Crohn's and Colitis Foundation of Canada
Dr. Falk Pharma
Elan Corporation
Enzo Biochem
European Federation of Crohn's and Ulcerative Colitis Associations
European Medicines Agency (EMEA)
Evonik Industries
Ferring Pharmaceuticals
Food and Drug Administration (US FDA)
Giaconda
Giuliani
GlaxoSmithKline
Interneuron
Isis Pharmaceuticals
Johnson & Johnson
King's College London
Kyorin Pharmaceutical Co.
Medarex
Merck & Co.
Miltenyi Biotec
Nycomed
Otsuka Pharmaceutical Group
PDL BioPharma
Pfizer
Probiotic Therapy Research Centre, Sydney, Australia
Procter & Gamble Pharmaceuticals
Prometheus Laboratories
Protein Design Labs
Royalty Pharma
Salix Pharmaceuticals
Sanofi
Schering-Plough
Shire Pharmaceuticals Group
Takeda Pharmaceutical Company
Tillotts Pharma
UCB
University of Auckland, New Zealand
Warner Chilcott
World Gastroenterology Organisation
To order this report:
Drug and Medication Industry: Inflammatory Bowel Diseases: World Drug Market 2011-2021
Drug and Medication Business News
Check our Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article